Influence of Patent Ductus Arteriosus and Its Treatment on Retinopathy of Prematurity.
10.3341/jkos.2013.54.5.728
- Author:
Myung Hun YOON
1
;
Wan Ki BAEK
;
Yeon Sung MOON
Author Information
1. Department of Ophthalmology, Inha University School of Medicine, Incheon, Korea. DrMYS@inha.ac.kr
- Publication Type:Original Article
- Keywords:
Patent ductus arteriosus;
PDA;
Retinopathy of prematurity;
Risk factor;
Very low birth weight
- MeSH:
Birth Weight;
Diterpenes;
Ductus Arteriosus, Patent;
Gestational Age;
Humans;
Incidence;
Infant;
Infant, Newborn;
Infant, Very Low Birth Weight;
Intensive Care, Neonatal;
Mass Screening;
Medical Records;
Retinopathy of Prematurity;
Retrospective Studies;
Risk Factors
- From:Journal of the Korean Ophthalmological Society
2013;54(5):728-735
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study investigated the influence of patent ductus arteriosus (PDA) and its treatment on incidence and progression of retinopathy of prematurity (ROP). METHODS: The authors retrospectively reviewed the medical records of 408 infants who underwent screening examinations for ROP at the Neonatal Intensive Care Unit of our hospital. RESULTS: The total incidence of ROP was 23.5% (96 out of 408) and the patients that needed treatment were 7.4% (30 out of 408). The mean birth weight and gestational age was 1406.1 grams and 30.67 weeks in patients without ROP, and 979.8 grams and 27.46 weeks in patients with ROP, respectively. In both total and very low birth weight (VLBW) patients, the incidence of ROP was higher in the PDA group than the non-PDA group, but the PDA group was an independent risk factor only in the VLBW group (p = 0.033). The incidence of threshold disease was not significantly different between the PDA and control groups (p = 0.757). There was no significant difference of incidence of ROP and threshold disease among the 3 treatment groups for PDA. CONCLUSIONS: In VLBW patients, the presence of PDA increased the risk of ROP and its progression, thus more attention is needed for PDA patients. However, there was no significant difference in ROP incidence and progression according to different PDA treatment methods.
